Featured Research

from universities, journals, and other organizations

Promising Anti-cancer Compound

Date:
September 25, 2008
Source:
World Journal of Gastroenterology
Summary:
Apoptin is a protein encoded by the chicken anemia virus and can cause apoptotic cell death. In this study, a secretory protein was designed by adding a secretory signal to the N-terminal of TAT-Apoptin. The study demonstrated that the SP-TAT-Apoptin induces apoptosis only in malignant cells, and its secretory property might greatly increase its potency for cancer therapy in vivo.

Apoptin is a protein encoded by the chicken anemia virus and can cause apoptotic cell death. In this study, a secretory protein was designed by adding a secretory signal to the N-terminal of TAT-Apoptin. The study demonstrated that the SP-TAT-Apoptin induces apoptosis only in malignant cells, and its secretory property might greatly increase its potency for cancer therapy in vivo.

New approaches in cancer therapy that facilitate selective targeting of cancers have been emerging in recent years. Apoptin represents a new anti-cancer tool in such new approaches with great potentials. Two routes can be taken using Apoptin or its encoding cDNA, i.e. as protein therapy or gene therapy.

A research team led by Prof. Duan from Life Sciences Institute of Northwest University used molecular biology,to generated a cDNA construct of SP-Tat-Apoptin fusion. Cancer cells transfected with this construct would express the recombinant Apoptin and apoptosis would be induced in them. By incorporating a synthetic signal peptide authors also expected Apoptin to be secreted outside of the transfected cells as Tat-Apoptin fusion protein and re-enter adjacent untransfected HepG2 cells, enabling the construct to act as both protein and gene therapeutic agent and increasing the potency of Apoptin in cancer therapy.

Having a synthetic signal peptide, the recombinant Apoptin was able to be secreted outside of the transfected cells and re-enter adjacent untransfected HepG2 cells. The recombinant protein was detected in the cytoplasm in HepG2 and HUVEC cells shortly after co-culture of the cells with the cell-free supernatant of the transfected CHO cell culture, indicating the secreted Tat-Apoptin fusion protein contained in the CHO cell culture media was able to enter these cells. The fusion protein was later found in the nucleus in HepG2 cells and induced HepG2 cell apoptosis.

The new secretory characteristic increased the possibility of Apoptin being used in cancer gene therapy. However, there are still a large number of unanswered questions regarding the mechanisms and therapeutic usage of Apoptin, and further studies are certainly required.

There are more HCC cell line used to confirm the results in our study, for example, Bel-7402 HCC cell line. The result about Bel-7402 will be discussed in future. Meanwhile in HUVEC cells, SP-Tat-Apoptin remained in the cytoplasm and no induction of apoptosis above the background level was observed.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Han SX, Ma JL, Lv Y, Huang C, Liang HH, Duan KM. Secretory Tat-Apoptin fusion protein induces apoptosis in hepatocellular carcinoma HepG2 cells. World J Gastroenterol, 2008; 14(23): 3642-3649 [link]

Cite This Page:

World Journal of Gastroenterology. "Promising Anti-cancer Compound." ScienceDaily. ScienceDaily, 25 September 2008. <www.sciencedaily.com/releases/2008/09/080925104353.htm>.
World Journal of Gastroenterology. (2008, September 25). Promising Anti-cancer Compound. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2008/09/080925104353.htm
World Journal of Gastroenterology. "Promising Anti-cancer Compound." ScienceDaily. www.sciencedaily.com/releases/2008/09/080925104353.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins